a-UMG1

a-UMG1 is an afucosylated, humanized monoclonal antibody directed against a specific glycosylated oncofetal epitope of CD43, designated as UN1. This epitope is highly and selectively expressed on malignant T-cell acute lymphoblastic leukemia (T-ALL) cells, particularly within the cortical T-ALL (EGIL T3) subgroup. By utilizing glycoengineering to remove fucose from the Fc region, a-UMG1 exhibits enhanced binding affinity for FcγRIIIa (CD16) on effector cells, thereby potently inducing antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against leukemia cells. Preclinical studies in orthotopic and subcutaneous T-ALL mouse models have demonstrated that a-UMG1 can significantly delay tumor growth and improve survival, especially when combined with NK cell-based therapies or chemotherapeutic agents like methotrexate and doxorubicin, which have been shown to upregulate the UN1 epitope.

Other names

afucosylated UMG1